This study investigates advanced pancreatic cancer. Participants will receive either a combination of albumin-bound paclitaxel and gemcitabine or the same combination with an additional investigational medication, S-1.
The purpose of this study is to evaluate the effectiveness and safety of these treatment options for patients with advanced pancreatic cancer.
- Who can participate: Participants must be 18 years or older with a diagnosis of pancreatic ductal adenocarcinoma and should not have received prior systemic treatment for advanced pancreatic cancer.
- Study details: Participants will receive treatment with albumin-bound paclitaxel and gemcitabine, with or without S-1. The study includes a placebo, which looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand